Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.02 AUD
Change Today 0.00 / 0.00%
Volume 4.2M
POH On Other Exchanges
Symbol
Exchange
Stuttgart
OTC US
OTC US
As of 1:55 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

phosphagenics ltd (POH) Snapshot

Open
A$0.02
Previous Close
A$0.02
Day High
A$0.02
Day Low
A$0.02
52 Week High
09/10/14 - A$0.10
52 Week Low
09/4/15 - A$0.02
Market Cap
21.5M
Average Volume 10 Days
3.7M
EPS TTM
A$-0.01
Shares Outstanding
1.3B
EX-Date
08/22/97
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHOSPHAGENICS LTD (POH)

Related News

No related news articles were found.

phosphagenics ltd (POH) Related Businessweek News

No Related Businessweek News Found

phosphagenics ltd (POH) Details

Phosphagenics Limited, a research-based biotechnology company, produces, sells, and licenses products for the pharmaceutical, cosmetics, and animal health industries. The company is involved in the commercialization of therapeutic products using its targeted penetration matrix technology, a drug delivery system that enhances human and animal health. Its Skin Care segment provides a range of products to enhance the appearance of skin. The company’s Pain Portfolio segment focuses on enhancing the delivery of opioids used for pain treatment through the skin. It serves customers in Australia, Switzerland, the United States, India, Brazil, and other countries. The company was formerly known as Vital Capital Limited and changed its name to Phosphagenics Limited in 2004. Phosphagenics Limited is based in Clayton, Australia.

41 Employees
Last Reported Date: 02/26/15

phosphagenics ltd (POH) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: A$166.2K
General Manager of Operations and Production
Total Annual Compensation: A$151.0K
General Counsel
Total Annual Compensation: A$244.7K
Vice President of Business Development & Comm...
Total Annual Compensation: A$229.6K
Vice President of Product Development
Total Annual Compensation: A$24.5K
Compensation as of Fiscal Year 2014.

phosphagenics ltd (POH) Key Developments

Phosphagenics Limited Announces Unaudited Consolidated Earnings Results for the Half Year Ended June 30, 2015

Phosphagenics Limited announced unaudited consolidated earnings results for the half year ended June 30, 2015. For the period, the company reported total revenue was AUD 978,000 against AUD 459,000 a year ago. Loss before income tax was AUD 13,405,000 against AUD 2,118,000 a year ago. Loss from continuing operations was AUD 13,405,000 against AUD 2,118,000 a year ago. Loss after income tax was AUD 13,900,000 against AUD 2,785,000 a year ago. Diluted loss per share from continuing operations was 1.06 cents against 0.20 cents a year ago. Diluted loss per share was 1.10 cents against 0.27 cents a year ago. Net cash outflow from operating activities was AUD 4,825,000 against AUD 1,170,000 a year ago. Purchase of plant and equipment was AUD 22,000 against AUD 13,000 a year ago.

Harry Rosen Steps Down as President and Executive Director of Phosphagenics Limited

Phosphagenics Limited announced Mr. Harry Rosen, founder and former CEO, will from date step down as President and Executive Director of the company.

Phosphagenics Limited Announces Management Change

Phosphagenics Limited announced that its current Chairman and Non-Executive Director, Mr. Lawrence Gozlan, has decided to step down from the Board to focus on all his other business interests and commitments, which are significant and growing. The role of Interim Chairman will be taken by Mr. Peter Lankau who was recently appointed to the Board. Mr. Lankau has considerable experience in the pain industry and is an ex-CEO of Endo Pharmaceuticals Inc. He has served on multiple boards.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
POH:AU A$0.02 AUD 0.00

POH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Durect Corp $2.06 USD +0.04
View Industry Companies
 

Industry Analysis

POH

Industry Average

Valuation POH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.6x
Price/Book 0.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHOSPHAGENICS LTD, please visit www.phosphagenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.